Key Takeaway: Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company, will participate in the Canaccord Genuity 43rd Annual Growth Conference. The event features a fireside chat scheduled for 12:00 p.m. ET. Nkarta is focused on developing engineered natural killer cell therapies, utilizing advanced technologies like CRISPR for improving cancer treatment effectiveness. A webcast of the event will be available on their website, allowing broader access to the discussion.
Price reaction · baseline $2.2 (2023-08-02 close) · hit after-hours · clean, no other NKTX news in the window
day 0 close
+0.5%
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively participating in investor relations, highlighting transparency.
The company is advancing promising NK cell therapies with significant potential.
Their technology combines various innovative methods, enhancing treatment efficacy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+124%
120-day peak, hindsight
Typical move
7.6%
average across 3 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
NKX101- CAR NK cell therapy
Phase 1 · Relapsed/Refractory AML
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation at an upcoming investor conference:
Canaccord Genuity 43rd Annual Growth Conference
12:00 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Frequently Asked Questions
What event will Nkarta participate in?
Nkarta will participate in the Canaccord Genuity 43rd Annual Growth Conference.
When is Nkarta's fireside chat scheduled?
The fireside chat is scheduled for 12:00 p.m. ET.
Where can I watch Nkarta's webcast?
The webcast will be available on Nkarta's Investors section of their website.
How long will the webcast replay be available?
The replay will be archived for approximately 90 days.
What therapies is Nkarta developing?
Nkarta is developing engineered natural killer (NK) cell therapies.